Chimeric antigen receptor (CAR)-T cell therapy is rapidly advancing as cancer treatment, however, designing an optimal CAR remains challenging. A single-chain variable fragment (scFv) is generally used as CAR targeting moiety, wherein the complementarity-determining regions (CDRs) define its specificity. We report here that the CDR loops can cause CAR clustering, leading to antigen-independent tonic signalling and subsequent CAR-T cell dysfunction. We show via CARs incorporating scFvs with identical framework and varying CDR sequences that CARs may cluster on the T cell surface, which leads to antigen-independent CAR-T cell activation, characterized by increased cell size and interferon (IFN)-& gamma; secretion. This results in CAR-T ce...
Redirecting the recognition specificity of T lymphocytes to designated tumour cell surface antigens ...
Insufficient reactivity against cells with low antigen density has emerged as an important cause of ...
International audienceChimeric antigen receptor (CAR) T cell therapy relies on the activity of a lar...
Chimeric antigen receptor (CAR)-T cell therapy is rapidly advancing as cancer treatment, however, de...
This study was designed to evaluate differences in gene expression in between different CAR-T cell c...
Chimeric antigen receptor T (CAR-T) cells are effective serial killers with a faster off-rate from d...
Chimeric antigen receptors (CARs) repurpose natural signaling components to retarget T cells to refr...
The chimeric antigen receptor (CAR) directs T cells to target and kill specific cancer cells. Despit...
© 2016 Dr Alexander DavenportDespite the success of autologous chimeric antigen receptor (CAR) T cel...
Chimeric antigen receptor (CAR) tonic signaling, defined as spontaneous activation and release of pr...
The advent of chimeric antigen receptor (CAR) T cells expedited the field of cancer immunotherapy en...
Chimeric antigen receptors (CARs) repurpose natural signaling components to retarget T cells to refr...
Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the therapeuti...
Adoptive T-cell therapy has emerged as one of the most promising treatment modalities for cancer. CD...
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological...
Redirecting the recognition specificity of T lymphocytes to designated tumour cell surface antigens ...
Insufficient reactivity against cells with low antigen density has emerged as an important cause of ...
International audienceChimeric antigen receptor (CAR) T cell therapy relies on the activity of a lar...
Chimeric antigen receptor (CAR)-T cell therapy is rapidly advancing as cancer treatment, however, de...
This study was designed to evaluate differences in gene expression in between different CAR-T cell c...
Chimeric antigen receptor T (CAR-T) cells are effective serial killers with a faster off-rate from d...
Chimeric antigen receptors (CARs) repurpose natural signaling components to retarget T cells to refr...
The chimeric antigen receptor (CAR) directs T cells to target and kill specific cancer cells. Despit...
© 2016 Dr Alexander DavenportDespite the success of autologous chimeric antigen receptor (CAR) T cel...
Chimeric antigen receptor (CAR) tonic signaling, defined as spontaneous activation and release of pr...
The advent of chimeric antigen receptor (CAR) T cells expedited the field of cancer immunotherapy en...
Chimeric antigen receptors (CARs) repurpose natural signaling components to retarget T cells to refr...
Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the therapeuti...
Adoptive T-cell therapy has emerged as one of the most promising treatment modalities for cancer. CD...
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological...
Redirecting the recognition specificity of T lymphocytes to designated tumour cell surface antigens ...
Insufficient reactivity against cells with low antigen density has emerged as an important cause of ...
International audienceChimeric antigen receptor (CAR) T cell therapy relies on the activity of a lar...